First 4 patients staggered over 4 months, FDA mandate for safety.
The rest of the patients will take 4-8 months.
MD Anderson sees 40 AML patients every month but they want to choose the right patients.
The patient population we're treating are in the adverse group.
Of that group, after the first 2 months the remission rate is 45-60%. Of the 45-60%, 80% relapse.
If we can pump up that remission rate by 20-35% and deep remission from 15-20% to 40-50%, we should see overall survival increase 20-35% but it could be more.
Overall survival with this patient population is 30-40% after a year and 10-15% after 4 years.
We should have a good idea of efficacy within the first couple of months of the trials patient population being treated.
CHM Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)